Profil
Ebrahim S.
Delpassand is the founder of RadioMedix, Inc. and currently holds the titles of Chairman and Chief Executive Officer.
Aktive Positionen von Ebrahim S. Delpassand
| Unternehmen | Position | Beginn |
|---|---|---|
RadioMedix, Inc.
 RadioMedix, Inc. BiotechnologyHealth Technology RadioMedix, Inc. is a clinical stage biotechnology company based in Houston, TX, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The private company commercializes radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy. The company covers the entire value chain from drug discovery to sponsoring and conducting clinical trials. The company has established contract service facilities for academic and industrial partners, including a drug discovery center, pre-clinical core facility, and a CGMP manufacturing and analytical suite for human clinical trials and commercial phase manufacturing of the radiopharmaceuticals. The company has also established a large-scale post-approval commercial manufacturing facility known as the Spica Center. The company's pipeline includes Detectnet™, a diagnostic agent for management of somatostatin expressing neuroendocrine cancers using PET/CT technology. The company was founded by Ebrahim S. Delpassand and he has been the CEO since incorporation. | Vorstandsvorsitzender | 01.01.2006 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
RadioMedix, Inc.
RadioMedix, Inc. BiotechnologyHealth Technology RadioMedix, Inc. is a clinical stage biotechnology company based in Houston, TX, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The private company commercializes radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy. The company covers the entire value chain from drug discovery to sponsoring and conducting clinical trials. The company has established contract service facilities for academic and industrial partners, including a drug discovery center, pre-clinical core facility, and a CGMP manufacturing and analytical suite for human clinical trials and commercial phase manufacturing of the radiopharmaceuticals. The company has also established a large-scale post-approval commercial manufacturing facility known as the Spica Center. The company's pipeline includes Detectnet™, a diagnostic agent for management of somatostatin expressing neuroendocrine cancers using PET/CT technology. The company was founded by Ebrahim S. Delpassand and he has been the CEO since incorporation. | Health Technology |
